CRISPR-Cas9 Germline Editing: Full Steam Ahead to Revolutionary Profit or Revolutionary Public Medicine?
DOI:
https://doi.org/10.18192/uojm.v8i2.3741Keywords:
CRISPR-cas9, germline editing, patents, gene editingAbstract
The CRISPR-Cas9 system uses precise germline genome editing, which enables the mutagenesis of disease sequences in embryonic DNA, thus enabling the birth of healthy individuals who would otherwise inherit genetic diseases. In 2012, the scientific community rushed to claim intellectual property in anticipation of CRISPR’s future economic potential. As the war for commercial territory forges ahead, the question of public accessibility and affordability has largely gone unaddressed. The current drive towards total CRISPR-Cas9 commercialization will lead to exorbitant costs of accessing life-giving treatment, especially in regulatory frameworks that prohibit federal funding of germline editing research.
Downloads
Published
2018-11-15
Issue
Section
Commentary
License
- Authors publishing in the UOJM retain copyright of their articles, including all the drafts and the final published version in the journal.
- While UOJM does not retain any rights to the articles submitted, by agreeing to publish in UOJM, authors are granting the journal right of first publication and distribution rights of their articles.
- Authors are free to submit their works to other publications, including journals, institutional repositories or books, with an acknowledgment of its initial publication in UOJM.
- Copies of UOJM are distributed both in print and online, and all materials will be publicly available online. The journal holds no legal responsibility as to how these materials will be used by the public.
- Please ensure that all authors, co-authors and investigators have read and agree to these terms.
- Works are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
